AMBS News Amarantus BioSciences Co-Founders hon

SUNNYVALE, Calif. , Sept. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California -based biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com's 13 ^th annual "50 Most Important African-Americans in Technology" for 2012. The selectees will gather in Washington, D.C. January 15 ^th , 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).

Dr. John W. Commissiong , Amarantus' Chief Scientific Officer, is the former Head of the Neurotrophic Factors Group at the National Institute of Neurological Disorders and Stroke (NINDS) who discovered and patented MANF. Gerald E. Commissiong , the Company's President & CEO, graduated from Stanford University 's Management Science and Engineering program with a focus in Financial Decisions. Their bios can be viewed online at: http://www.amarantus.com/about-us/management-team.html .